Antibodies against HIV-1 from phage display libraries: Mapping of an immune response and progress towards antiviral immunotherapy

Chemical Immunology

Volumn 65, Issue , 1997, Pages 18-56

  Parren, Paul W H I ^a   Burton, Dennis R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ANIMALS; BACTERIOPHAGES; EPITOPE MAPPING; GENE LIBRARY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOTHERAPY;

EID: 0031027984     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (163)

1. Behring E, Kitasato S: Ueber das Zustandekommen der Diphterie-Immunität und der Tetanus-Immunität bei Thieren. Dt Med Wochenschr 1890;16:1113.
2. Behring EA: Die Geschichte der Diphtherie. Leipzig, Thieme, 1983, p 186.
3. Behring EA: Das neue Diphtherieheilmittel. Berlin, Hering, 1894, p 40.
4. Bowman JM: The prevention of Rh immunization. Trans Med Rev 1983;2:129-150.
5. Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI: Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984;ii: 255-256.
6. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-497.
7. Carson DA, Freimark BD: Human lymphocyte hybridomas and monoclonal antibodies. Adv Immunol 1986;38:275-311.
8. Casali P, Notkins AL: Probing the human B-cell repertoire with EBV: Polyreactive. Annu Rev Immunol 1989;7:513-535.
9. Parren PWHI: Preparation of genetically engineered monoclonal antibodies for human immunotherapy. Hum Antibody Hybridomas 1992;3:137-145.
10. Lum LG, Burns E, Janson MM: IgG anti-tetanus toxoid antibody synthesis by human bone marrow. I. Two distinct populations of marrow B cells and functional differences between marrow and peripheral blood B cells. J Clin Immunol 1990;10:255-264.
11. Boulianne GL, Hozumi N, Shulman MJ: Production of functional chimaeric mouse/human antibody. Nature 1984;312:643-646.
12. Morrison SL, Johnson MJ, Herzenberg LA: Chimeric human antibody molecules: Mouse antigen-binding domains with human constant domains. Proc Natl Acad Sci USA 1984;81:6851-6855.
13. Neuberger MS, Williams GT, Mitchell EB: A hapten-specific chimeric immunoglobulin E antibody which exhibits human physiological effector function. Nature 1985;314:268-271.
14. Bruggemann M, Williams GT, Bindon MR, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS: Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-1361.
15. Parren PWHI, Geerts MEJ, Boeije LCM, Aarden LA: Induction of T-cell proliferation by recombinant mouse and chimeric mouse/human anti-CD3 monoclonal antibodies. Res Immunol 1991;142:749-763.
16. Jones PT, Dear PH, Foot J: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986;321:522-525.
17. Verhoeyen M, Milstein C, Winter G: Reshaping human antibodies: Grafting an antilysosyme activity. Science 1988;239:1534-1536.
18. Co MS, Queen C: Humanized antibodies for therapy. Nature 1991;351:501-502.
19. Bruggemann M, Winter G, Waldmann H, Neuberger MS: The immunogenicity of chimeric antibodies. J Exp Med 1989;170:2153-2157.
20. Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 1988;332:323-327.
21. Better M, Chang CP, Robinson RR, Horwitz AH: Escherichia coli secretion of an active chimeric antibody fragment. Science 1988;240:1041-1043.
22. Orlandi R, Gussow DH, Jones PT, Winter G: Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:3833-3837.
23. Larrick JW, Danielsson L, Brenner CA, Abrahamson M, Fry KE, Borrebaeck CAK: Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and the polymerase chain reaction. Biochem Biophys Res Commun 1989;160:1250-1256.
24. Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA: Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989;246:1275-1281.
25. Persson MA, Caothien RH, Burton DR: Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci USA 1991;88:2432-2436.
26. Mullinax RL, Gross EA, Amberg JF, Hay BN, Hogrefe HH, Kubitz MM, Greener A, Alting-Mees M, Ardourel D, Short JM, Sorge JA, Shopes B: Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage lambda immunoexpression library. Proc Natl Acad Sci USA 1990;87:8095-8099.
27. Burton DR, Barbas III CF: Human antibodies from combinatorial libraries. Adv Immunol 1994; 57:191-280.
28. Smith GP: Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 1985;228:1315-1317.
29. Scott JK, Smith GP: Searching for peptide ligands with an epitope library. Science 1990;249:386-390.
30. Devlin JJ, Panganiban LC, Devlin PE: Random peptide libraries: A source of specific protein binding molecules. Science 1990;249:404-406.
31. Cwirla SE, Peters EA, Barrett RW, Dower WJ: Peptides on phage: A vast library of peptides for identifying ligands. Proc Natl Acad Sci USA 1990;87:6378-6382.
32. McCafferty J, Griffiths AD, Winter G, Chiswell DJ: Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 1990;348:552-554.
33. Kang AS, Barbas III CF, Janda KD, Benkovic SJ, Lerner RA: Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc Natl Acad Sci USA 1991;88:4363-4366.
34. Barbas III CF, Kang AS, Lerner RA, Benkovic SJ: Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. Proc Natl Acad USA 1991;88:7978-7982.
35. Stevens RH, Macy E, Morrow C, Saxon A: Characterization of a circulating subpopulation of spontaneous antitetanus toxoid antibody producing B cells following in vivo booster immunization. J Immunol 1979;122:2498-1504.
36. Thiele CJ, Morrow CD, Stevens RH: Multiple subsets of anti-tetanus toxoid antibody-producing cells in human peripheral blood differ by size, expression of membrane receptors, and mitogen reactivity. J Immunol 1981;126:1146-1153.
37. Ershler WB, Moore AL, Hacker MP: Specific in vivo and in vitro antibody response to tetanus toxoid immunization. Clin Exp Immunol 1982;49:552-558.
38. Volkman DJ, Allyn SP, Fauci AS: Antigen-induced in vitro antibody production in humans: Tetanus toxoid specific antibody synthesis. J Immunol 1982;129:107-112.
39. Barbas SM, Ditzel HJ, Salonen EM, Wei-Ping Y, Silverman GJ, Burton DR: Human autoantibody recognition of DNA. Proc Natl Acad Sci USA 1995;92:2529-2533.
40. Willaimson RA, Burioni R, Sanna PP, Partridge LJ, Barbas III CF, Burton DR: Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc Natl Acad Sci USA 1993;90:4141-4145.
41. Barbas III CF: Recent advances in phage display. Curr Opin Biotechnol 1993;4:526-530.
42. Barbas SM, Barbas III CF: Filamentous phage display. Fibrinolysis 1994;8(suppl 1):245-252.
43. Cortese R, Monaci P, Nicosia A, Luzzago A, Felici F, Galfré G, Pessi A, Tramontano A, Sollazzo M: Identification of biologically active peptides using random libraries displayed on phage. Curr Opin Biotechnol 1995;6:73-80.
44. Cortese R, Felici F, Galfré G, Luzzago A, Monaci P, Nicosia A: Epitope discovery using peptide libraries displayed on phage. Trends Biotechnol 1994;12:262-266.
45. Fong S, Doyle LV, Devlin JJ, Doyle MV: Scanning whole cells with phage-display libraries: Identification of peptide ligands that modulate cell function. Drug Dev Res 1994;33:64-70.
46. Gallop MA, Barrett RW, Dower WJ, Fodor SPA, Gordon EM: Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. J Med Chem 1994;37:1233-1251.
47. Gordon EMM, Barrett RW, Dower WJ, Fodor SPA, Gallop MA: Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. J Med Chem 1994;37:1385-1401.
48. Scott JK, Craig L: Random peptide libraries. Curr Opin Biotechnol 1994;9:40-48.
49. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR: Making antibodies by phage display technology. Annu Rev Immunol 1994;12:433-455.
50. Walker NR, Lund J, Thompson KM, Jefferis R: Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing FcgammaRI and/or Fcgamma-RII receptors. Biochem J 1989;259:347-353.
51. Tao MH, Morrison SL: Studies of aglycosylated chimeric mouse-human IgG: Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989;143:2595-2601.
52. Wright A, Shin SU: Production of genetically engineered antibodies in myeloma cells: Design, expression and applications: in Lerner A, Burton DR (eds): Methods: A Companion to Methods in Enzymology. Orlando, Academic Press, 1991, pp 125-135.
53. Bebbington CR: Expression of antibody genes in nonlymphoid mammalian cells; in Lerner RA, Burton DR (eds): Methods: A Companion to Methods in Enzymology. Orlando, Academic Press, 1991.
54. Hasemann CA, Capra JD: High-level production of a functional immunoglobulin heterodimer in a baculovirus expression system. Proc Natl Acad Sci USA 1990;87:3942-3946.
55. Bender E, Woof JM, Atkin JD, Barker MD, Bebbington CR, Burton DR: Recombinant human antibodies: Linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. Hum Antibody Hybridomas 1993;4:74-79.
56. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PWHI, Sawyer LSW, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, Barbas III CF: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027.
57. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT: High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Bio/Technology 1992;10:169-175.
58. Chanock RM, Crowe Jr JE, Murphy BR, Burton DR: Human monoclonal antibody Fab fragments cloned from combinatorial libraries: Potential usefulness in prevention and/or treatment of major human viral diseases. Infect Agents Dis 1993;2:118-131.
59. Krugman SR, Ward R, Giles JP, Jacobs AM: Infectious hepatitis: Studies on the effect of gamma globulin and on the incidence of inapparent infection. JAMA 1960;174:83-90.
60. Snydman DR: Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 1990;12:S839-S848.
61. Snydman DR, Werner BG, Heinze-Lacy B, Beredi BP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL, Levey AS, Strom TB, Carpenter CB, Levey RH, Harman WE, Zimmerman ZE, Shapiro ME, Steinman T, LoGerfo F, Idelson B, Schroter GPJ, Levin MJ, Mclver J, Leszczynski J, Grady GF: Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317:1049-1054.
62. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Rodriguez WJ, Meissner C, Welliver RC, Hemming VG, RSVIG Study Group: Respiratory syncytial virus (RSV) immune globulin (IG) prevents severe lower respiratory infection (LRI) in high risk children. Pediatr Res 1993;33:169A.
63. Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, Sun TS, Szmuness W: Efficacy of hepatitis B immune globulin for prevention of perinatal. Hepatology 1983;3:135-141.
64. Orenstein WA, Heymann DL, Ellis RL, Rosenberg RL, Nakano J, Halsey NA, Overturf GD, Hayden DF, Witte JJ: Prophylaxis of varicella in high risk children: Dose response effect of zoster immune globulin. J Pediatr 1981;98:368-373.
65. Loofbourow JC, Cabasso VJ, Roby RE, Anuskiewicz W: Rabies immune globulin (human) clinical trials and dose determination. JAMA 1971;217:1825-1831.
66. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990;345:622-625.
67. Girard M, Kieny MP, Pinter A, Barre-Sinousi F, Nara PL, Kolbe H, Kusumi K, Chaput A, Reinhart T, Muchmore E, Ronco J, Kaczorek M, Gomard E, Gluckman J-C, Fultz PN: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:542-546.
68. Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, Schwartz D, Gorse G, Belshe R, Clements ML, Byrn RA: Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 1994;8:591-601.
69. Bruck C, Thiriart C, Fabry L, Francotte M, Pala P, Van Opstal O, Culp J, Rosenberg M, DeWilde M, Heidt P, Heeney J: HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccines 1994;12:1141-1148.
70. Berman PW, Eastman DJ, Nakamura GR, Obijeski JF, Francis D, Gregory TJ, Murthy KK: Apparent protection of MN-rgp120-immunized chimpanzees from infection with a primary isolate of HIV-1; in Chanock RM, Brown F, Ginsberg HS, Norrby E (eds): Vaccines 95; Molecular Approaches to the Control of Infectious Diseases. Plainview, Cold Spring Harbor Laboratory Press, 1995, pp 143-148.
71. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg JW, Murthy KK: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992;355:728-730.
72. Giavedoni LD, Planelles V, Haigwood NL, Ahmad S, Kluge JD, Mathas ML, Gardner MB, Luciw PA, Yilma TD: Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol 1993;67:577-583.
73. Israel ZR, Edmondson PF, Maul DH, O'Neil SP, Mossman SP, Thiriart C, Fabry L, Van Opstal O, Bruck C, Bex F, Burny A, Fultz PN, Mullins JI, Hoover EA: Incomplete protection but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol 1994; 68:1843-1853.
74. Siegel F, Kurth R, Norley S: Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SlVagm infection in the African green monkey natural host. J Acquir Immune Defic Syndr 1995;8:217-226.
75. sm infection by passive immunization in cynomolgus monkeys. Nature 1991;352: 436-438.
76. Kent KA, Kitchin P, Mills KHG, Page M, Taffs F, Corcoran T, Silvera P, Flanagan B, Powell C, Rose J, Ling C, Aubertin AM, Scott EJ: Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251. AIDS Res Hum Retroviruses 1994;10:189-194.
77. Levy J, Youvan T, Lee ML, Passive Hyperimmune Therapy Study Group: Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: Results of a 12-month multicenter double-blind controlled trial. Blood 1994;84:2130-2135.
78. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF III, Burton DR, Ho DD: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.
79. Crothers DM, Metzger H: The influence of polyvalency on the binding properties of antibodies. Immunochemistry 1972;9:341-357.
80. Hornick CL, Karush F: Antibody affinity - III the role of multivalence. Immunochemistry 1972; 9:325-340.
81. Mason DW, Williams AF: Kinetics of antibody reactions and the analysis of cell surface antigens; in Weir DM (ed): Handbook of Experimental Immunology, Oxford, Blackwell, 1986.
82. V fragments with high avidity in Escherichia coli. Biochemistry 1992;31:1579-1584.
83. Keller R: The stability of neutralization of poliovirus by native antibody and enzymatically derived fragments. J Immunol 1966;96:96-106.
84. Icenogle J, Shiwen H, Duke G, Gilbert S, Rueckert R, Anderegg J: Neutralization of poliovirus by a monoclonal antibody: Kinetics and stoichiometry. Virology 1983;127:412-425.
85. Thomas AAM, Brioen P, Boeyé A: A monoclonal antibody that neutralizes poliovirus by cross-linking virions. J Virol 1985;54:7-13.
86. Ruggeri FM, Greenberg HB: Antibodies to the trypsin cleavage peptide VP8 neutralize rotavirus by inhibiting binding of virions to target cells in culture. J Virol 1991;65:2211-2219.
87. Yoden S, Kida H, Yanagawa R: Is bivalent binding of monoclonal antibodies to different antigenic areas on the hemagglutinin of influenza virus required for neutralization of viral infectivity? Virology 1985;85:209-216.
88. Dimmock NJ: Neutralization of animal viruses. Curr Top Microbiol Immunol 1993;183:1-149.
89. Buchmeier MJ, Lewicki HA, Talbot PJ, Knobler RL: Murine hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody. Virology 1984;132:261-270.
90. Talbot PJ, Salmi AA, Knobler PJ, Buchmeier MJ: Topographical mapping of murine hepatitis virus-4 (strain JHM): Correlation with biological activities. Virology 1984;132:250-260.
91. Rector JT, Lausch RL, Oakes JE: Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 12 infection. Infect Immun 1982;38:168-174.
92. Kümel G, Kaerner HC, Levine M, Schröder CH, Glorioso JC: Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity. J Virol 1985;56:930-937.
93. Balachandran N, Bacchetti S, Rawls WE: Protection against lethal challenge of balb/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex type 2. Infect Immun 1982;37:1131-1137.
94. Deregt D, Gifford GA, Ljaz MK, Watts TC, Gilchrist JE, Haines DM, Babiuk LA: Monoclonal antibodies to bovine coronavirus Glycoproteins E2 and E3: Demonstration of in vivo virus-neutralizing activity. J Gen Virol 1989;70:993-998.
95. Mathews JH, Roehrig JT, Trent DW: Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J Virol 1985;55:594-600.
96. Baldridge JR, Buchmeier MJ: Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: Mother-to-baby transfer of humoral protection. J Virol 1992;66: 4252-4257.
97. Schlesinger JJ, Foltzer M, Chapman S: The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 1993;192:132-141.
98. Schlesinger JJ, Chapman S: Neutralizing F(ab′)2 fragments of protective monclonal antibodies to yellow fever virus (YF) envelope protein fails to protect mice against lethal YF encephalitis. J Gen Virol 1995;76:217-220.
99. McCullough KC, Crowther JR, Butcher RN, Carpenter WC, Brocchi E, Cappucci L, De Simone F: Immune protection against foot-and-mouth disease virus studied using neutralizing and non-neutralizing concentrations of monoclonal antibodies. Immunology 1986;58:421-428.
100. Boere WAM, Benaissa-Trouw BJ, Harmsen T, Erich T, Kraaijeveld CA, Snippe H: Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. J Virol 1985;54:546-551.
101. Prince GA, Hemming VG, Horswood RL, Baron PA, Murphy BR, Chanock RM: Mechanism of antibody-mediated clearance in immunotherapy of respiratory syncytial virus infection of cotton rats. J Virol 1990;64:3091-3092.
102. Mariani G, Strober W: Immunoglobulin metabolism; in Metzger H (ed): Fc Receptors and the Action of Antibodies. Washington, American Society for Microbiology, 1990.
103. Crowe JE Jr, Murphy BR, Chanock RM, Williamson RA, Barbas CF III, Burton DR: Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci USA 1994;91: 1386-1390.
104. Parren PWHI, Ditzel HJ, Gulizia RJ, Binley JM, Barbas CF III, Burton DR, Mosier DE: Protection against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 1995;9:F1-F6.
105. Robey WG, Arthur LO, Matthews TJ, Langlois A, Copeland TD, Lerche NW, Oroszlan S, Bolognesi DP, Gilden RV, Fischinger PJ: Prospect for prevention of human immunodeficiency virus infection: Purified 120 kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci USA 1986;83:7023-7027.
106. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, Matthews TJ: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768-6772.
107. Steimer KS, Scandella CJ, Skiles PV, Haigwood NL: Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 1991;254:105-108.
108. Moore JP, Sattentau QJ, Wyatt R, Sodroski J: Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol 1994;68:469-484.
109. Moore JP, Ho DD: HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. AIDS 1995;9(suppl A):S117-S136.
110. Javaherian K, Langlois AJ, LaRosa GJ, Profy AT, Bolgnesi DP, Herlihy WC, Putney SD, Matthews TJ: Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990;250:1590-1593.
111. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Holley LH, Karplus M, Bolognesi DP, Matthews TJ, Emini EA, Putney SD: Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249:932-935.
112. Moore JP, Nara PL: The role of the V3 loop in HIV infection. AIDS 1991;5(suppl 2):S21-S33.
113. Moore JP, Ho DD: Antibodies to discontinuous or conformationally-sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 1993;67:863-875.
114. Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, Sun N-C, Robinson JE: Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991;65:489-493.
115. Tilley SA, Honnen WJ, Racho ME, Hilgartner M, Pinter A: A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. Res Virol 1991; 142:247-259.
116. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, Sodroski J: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993;67:3978-3988.
117. Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994;68:8312-8320.
118. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type I. J Virol 1996;70:1100-1108.
119. Pincus SH, Messer KG, Nara PL, Blattner A, Colclough G, Reitz M: Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Invest 1994; 93:2505-2513.
120. Muster T, Guinea R, Trkola A, Purtsher M, Klima A, Steindl F, Palese P: Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994;68:4031-4034.
121. Conley AJ, Kessler JA II, Boots LJ, Tung J-S, Arnold BA, Keller PM, Shaw AR, Emini EA: Neutralization of divergent human immunodeficiency type 1 variants and primary isolates by IAM-41-2F5, and anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994;91:3348-3352.
122. Daar ES, Li XL, Moudgil T, Ho DD: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990;87:6574-6578.
123. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, Norcross MA: Cryptic nature of envelope V3 region epitopes protects primary human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-6013.
124. Burton DR, Barbas CF III, Persson MA, Koenig S, Chanock RM, Lerner RA: A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991;88:10134-10137.
125. Barbas CF III, Collet TA, Amberg W, Roben P, Binley JM, Hoekstra D, Cababa D, Jones TM, Williamson RA, Pilkington GR, Haigwood NL, Cabezas E, Satterthwait AC, Sanz I, Burton DR: Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 1993;230:812-823.
126. Moore JP, Ho DD: Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 1993;67:863-875.
127. Barbas CF III, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E, Burton DR: Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992;89:9339-9343.
128. Helseth E, Kowalski M, Gabuzda D, Olshevsky U, Haseltine W, Sodroski J: Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol 1990;64:2416-2420.
129. Hanson CV, Crawford-Miksza L, Sheppard HW: Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers. J Clin Microbiol 1990; 28:2030-2034.
130. Trkola A, Pomales AP, Yuan H, Korber B, Maddon PJ, Allaway G, Katinger H, Barbas CF III, Burton DR, Ho DD, Moore JP: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-6617.
131. Gauduin MC, Allaway GP, Maddon PJ, Barbas CF III, Burton DR, Koup RA: Effective ex vivo neutralization of plasma HIV-1 by recombinant immunoglobulin molecules. J Virol, in press.
132. Torbett BE, Picchio G, Mosier DE: Hu-PBL-SCID mice: A model for human immune function. AIDS and lymphoma genesis. Immunol Rev 1991;124:139-164.
133. Hesselton RM, Koup RA, Cromwell MA, Graham BS, Johns M, Sullivan JL: Human peripheral blood xenografts in the SCID mouse: Characterization of immunologic reconstitution. J Infect Dis 1993;168:630-640.
134. Koup TA, Hesselton RM, Safrit JT, Somasundran M, Sullivan JL: Quantitative assessment of human immunodeficiency virus type 1 replication in human xenografts of acute-infected Hu-PBL-SCID mice. AIDS Res Hum Retroviruses 1994;10:279-284.
135. Zuckier LS, Rodriguez LD, Scharff MD: Immunologic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med 1989;19:166-186.
136. Ditzel HJ, Parren PWHI, Binley JM, Sodroski J, Moore JP, Barbas CF III, Burton DR: Mapping the protein surface of HIV-1 gp120 using human monoclonal antibody libraries from phage display libraries, unpubl.
137. Ditzel HJ, Binley JM, Moore JP, Sodroski J, Sullivan N, Sawyer LSW, Hendry RM, Yang W-P, Barbas CF III, Burton DR: Neutralizing recombinant human antibodies to a conformational V2-and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated using an epitope-masking procedure. J Immunol 1995;154:895-908.
138. Helseth E, Olshevsky U, Furman C, Sodroski J: Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 1991;65:2119-2123.
139. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, Sodroski J: Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 1990;64:5701-5707.
140. Ditzel HJ, Parren PWHI, Sullivan N, Sodroski J, Sawyer LSW, Hendry RM, Pinter A, Dunlop N, Nara PL, Trkola A, Moore JP, Barbas CF III, Burton DR: A recombinant human Fab fragment directed against a conformation dependent epitope in the second variable region of HIV-1 gp120 neutralizes T-cell line-adapted strains of HIV-1 but primary isolates less efficiently, in preparation.
141. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
142. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
143. Binley JM, Ditzel HJ, Barbas CF III, Sullivan N, Sodroski J, Parren PWHI, Burton DR: Human antibody responses to HIV-1 gp41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses, in press.
144. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF III, Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-4828.
145. H segments. J Mol Biol 1992;227:799-817.
146. Sattentau QJ, Zolla-Pazner S, Poignard P: Epitope exposure on functional, olgomeric HIV-1 gp41 Molecules. Virology 1995;206:713-717.
147. Barbas CF III, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM, Nara PL, Burton DR: In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci USA 1994;91:3809-3813.
148. Yang W-P, Green K, Pinz-Sweeney S, Briones AT, Burton DR, Barbas CF III: CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 1995;254:392-403.
149. Sattentau Q, Parren PW, Burton DR: Unpubl.
150. Earl, PL, Broder CC, Long D, Lee SA, Peterson J, Chakrabarti S, Doms RW, Moss B: Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994;68:3015-3026.
151. Broder CC, Earl PL, Long D, Abedon ST, Moss B, Doms RW: Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci USA 1994;91:11699-11703.
152. Parren PWHI, Fisicaro P, Labrijn A, Binley JM, Yang W-P, Ditzel HJ, Barbas CF III, Burton DR: In vitro antigen 'challenge' of human antibody libraries for vaccine evaluation: The human immunodeficiency virus type 1 oligomer. J Virol 1996, in press.
153. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steidl F, Jungbauder A, Katinger H: Generation of human monoclonal antibodies against HIV-1 proteins: Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10:359-369.
154. Burton DR, Barbas CF III: Human antibodies to HIV-1 by recombinant DNA methods; in Norrby E (ed): Immunochemistry of AIDS. Chem Immunol Basel, Karger, 1993, vol 56, pp 112-126.
155. Vogt A, Kopp R, Maass G, Reich L: Poliovirus type 1: Neutralization by papain-digested antibodies. Science 1964;145:1447-1448.
156. Klinman NR, Long CA, Karush F: The role of antibody bivalence in the neutralization of bacteriophage. J Immunol 1967;99:1128-1133.
157. Ashe WK, Mage M, Mage R, Notkins AL: Neutralization and sensitization of herpes simplex virus with antibody fragments from rabbits of different allotypes. J Immunol 1968;101:500-504.
158. Rosenstein RW, Nisonoff A, Urh JW: Significance of bivalence of antibody in viral neutralization. J Exp Med 1971;134:1431-1441.
159. Merz DC, Scheid A, Choppin PW: Immunological studies of the functions of paramyxovirus glycoproteins. Virology 1981;109:94-105.
160. Roehrig JT, Hunt AR, Kinney RM, Mathews JH: In vitro mechanisms of monoclonal antibody neutralization of alphavirus. Virology 1988;165:66-73.
161. Colonno RJ, Callahan PL, Leippe DM, Rueckert RR, Tomassini JE: Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. J Virol 1989;63:36-42.
162. Kingsford L, Boucquey KH, Porter T, Cardoso TP: Effects of specific monoclonal antibodies on la crosse virus neutralization: Aggregation, inactivation by fab fragments, and inhibition of attachment to baby hamster kidney cells. Virology 1991;180:591-601.
163. Cheung SC, Dietzschold B, Koprowski H, Notkins AL, Rando RF: A recombinant human Fab expressed in escherichia coli neutralizes rabies virus. J Virol 1992;66:6714-6720.